Epidemiology and outcomes of pediatric transplant‐associated thrombotic microangiopathy in Hong Kong

Background Transplant‐associated thrombotic microangiopathy (TA‐TMA) is an under‐recognized yet potentially devastating complication of hematopoietic stem cell transplantation (HSCT) which had increased awareness in recent years. This report summarizes the demographics and outcomes of pediatric TA‐TMA in Hong Kong. Methods All patients aged below 18 years who underwent HSCT in the Hong Kong Children's Hospital and were diagnosed to have TA‐TMA during the 2‐year period from April 1, 2019 to March 31, 2021 were included. Results A total of 73 transplants (51 allogeneic and 22 autologous) in 63 patients had been performed. Six patients (four males and two females) developed TA‐TMA at a median duration of 2.5 months post‐HSCT. The incidence rate was 9.52%. Of the six TA‐TMA patients, five underwent allogenic one underwent autologous HSCT, respectively. Three of them were histologically proven. All four patients with cyclosporine had stopped the drug once TA‐TMA was suspected. Median six doses of eculizumab were administered to five out of six patients. Three patients died (two due to fungal infection and one due to acute‐on‐chronic renal failure) within 3 months upon diagnosis of TA‐TMA. Among three survivors, two stabilized with mild stage 2 chronic kidney disease (CKD) while the other suffered from stage 5 end‐stage CKD requiring lifelong dialysis. Conclusion In conclusion, recognition and diagnosis of TA‐TMA are challenging. Early recognition and prompt administration of complement blockage with eculizumab may be beneficial in selected cases. Further prospective research studies are recommended to improve the management and outcomes of TA‐TMA.